Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + HPV 9-valent vaccine in advanced cervical cancer
NCT06882447Phase 2Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by Subei People's Hospital. Primary endpoint: Objective Response Rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06882447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882447.